NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference

Rhea-AI Summary

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) will participate in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. CEO Alex Zwyer is scheduled for a live interview on September 29 from 1:55 PM to 2:15 PM ET. Attendees can access the interview here, with a replay available on the company website. NLS focuses on developing therapies for rare CNS disorders and is advancing its lead candidate, Quilience, for narcolepsy, which has Orphan Drug Designations in the U.S. and Europe.

STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to participate in a live interview and meet with investors at the Benzinga Healthcare Small Cap Conference to be held virtually on September 29-30, 2021.

Event Details:

Date: September 29, 2021
Time: 1:55pm - 2:15pm ET

Event Access: Please click this link to access the live interview. A replay will also be available on the Company's website at https://nls-pharma.com/

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience® in adult subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol^® (mazindol controlled-release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol^® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3^rd of narcoleptic patients are also diagnosed with ADHD.

Corporate Contact
Alex Zwyer, CEO
+41 41 618 80 00

Investor Relations Contact
Cindy Rizzo
+1 908-229-7050
www.nlspharma.com

SOURCE: NLS Pharmaceutics AG

View source version on accesswire.com:
https://www.accesswire.com/665344/NLS-Pharmaceutics-to-Participate-in-the-Benzinga-Healthcare-Small-Cap-Conference

FAQ

When is NLS Pharmaceutics' interview at the Benzinga Healthcare Small Cap Conference?

The interview is scheduled for September 29, 2021, from 1:55 PM to 2:15 PM ET.

What is the focus of NLS Pharmaceutics?

NLS Pharmaceutics focuses on developing therapies for rare and complex central nervous system disorders.

What is Quilience and its significance?

Quilience is NLS's lead product candidate, an extended-release formulation of mazindol, developed for the treatment of narcolepsy.

Has Quilience received any designations?

Yes, Quilience has received Orphan Drug Designations in both the U.S. and Europe for narcolepsy treatment.

What other studies has NLS Pharmaceutics conducted?

NLS completed a phase 2 study for Nolazol, a controlled-release form of mazindol, which successfully met all endpoints for ADHD treatment.